Table 4.
Phase I clinical trials with gene-engineered T cells in glioblastoma.
| Clinical Trial | Phase | CAR Generation | Target | Other Treatment | Indication | # Patients | OR (%) | CR (%) |
|---|---|---|---|---|---|---|---|---|
|
NCT00730613 26059190 |
I | First CD3z |
IL13Rα2 | SS | R GB | 3 | 0/3 (0) | 0/3 (0) |
|
NCT02208362 28029927 |
I | Second 41BB-CD3z |
IL13Rα2 | SS | R GB IL13Rα2+ |
1 | 1/1 (100) | 1/1 (100) |
|
NCT01109095 28426845 |
I | Second CD28-CD3z |
HER2 CMV pp65 |
SS | R GB HER2+ |
17 | 1/17 (6) | 0/17 (0) |
|
NCT02209376 28724573 |
I | Second 41BB-CD3z |
EGFRvIII | SS | R GB EGFRvIII+ |
10 | 0/10 (0) | 0/10 (0) |
|
NCT01454596 30882547 |
I | Third CD28-41BB-CD3z |
EGFRvIII | Cyclophosphamide, Fludarabine, IL-2 |
R GB EGFRvIII+ |
18 | 0/18 (0) | 0/18 (0) |
Abbreviations: SS, second surgical procedure; IL-2, interleukin 2; R, recurrent; GB, glioblastoma; OR, objective response; CR, complete response; both according to Response Assessment in Neuro-Oncology (RANO) criteria. Number of patients with responses = before dash. Total number of patients treated = after dash. Percentage of responses = between brackets (bold).